Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review

References

• Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763–775.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Hart L, Favret A, et al. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clin Breast Cancer. 2019;19(4):268–77.e1.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med [Internet]. 2020 [cited 2020 Jul 21]; Available from: 382 9 810–821
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes JF, Sestak I, et al. Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer–96-Month Follow-up of the Randomized IBIS-I Trial. JNCI J Natl Cancer Inst. 2007;99:272–282.
   Web of Science ®Google Scholar
• Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–1238.
   PubMed Web of Science ®Google Scholar
• Kim S-B, Dent R, Im S-A, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18(10):1360–1372.
   PubMed Web of Science ®Google Scholar
• Willemsen AECAB, Tol J, Van Erp NP, et al. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Target Oncol. 2019;14(4):441–451.
   PubMed Web of Science ®Google Scholar
• Raghupathi R, Patil C, Dhiman P. Drug-induced infiltrative lung disease with weekly paclitaxel in breast cancer: case series. J Cancer Res Ther. 2019.
   Web of Science ®Google Scholar
• Mitropoulou G, Daccord C, Sauty A, et al. Immunotherapy-Induced Airway Disease: a New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors. Respiration. 2020;99(2):181–186.
   PubMed Web of Science ®Google Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: a Systematic Review. J Clin Med [Internet]. 2018 [cited 2020 Aug 18];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209877/ 10 356
   PubMed Web of Science ®Google Scholar
• Blanchard A, Bouchard N. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. Curr Oncol. 2019;26(4):e571–3.
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K. Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. Oncol Lett. 2012;4(5):865–867.
   PubMed Web of Science ®Google Scholar
• Manuprasad A, Ganesan P, Mahajan V, et al. Docetaxel-induced lung injury: an under-recognized complication of a commonly used chemotherapeutic agent. Indian J Med Paediatr Oncol. 2019;40(2):208.
   Web of Science ®Google Scholar
• Li L, Mok H, and Jhaveri P, et al. Anticancer therapy and lung injury: molecular mechanisms. Expert Rev Anticancer Ther. 2018;18(10):1041–1057.
   PubMed Web of Science ®Google Scholar
• Schwaiblmair M, Behr W, Haeckel T, et al. Drug Induced Interstitial Lung Disease. Open Respir Med J. 2012;6(1):63–74.
   PubMedGoogle Scholar
• Rashdan S, Minna JD, and Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018;6(6):472–478.
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004;91(S2):S31–7.
   PubMedGoogle Scholar
• Charpidou AG, Gkiozos I, Tsimpoukis S, et al. Therapy-induced Toxicity of the Lungs: an Overview. Anticancer Res. 2009;29:631–639.
   PubMed Web of Science ®Google Scholar
• Reckzeh B, Merte H, Pflüger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(4):1071–1076.
   PubMed Web of Science ®Google Scholar
• Hoyt DG, Lazo JS. Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide. Biochem Pharmacol. 1994;48(9):1757–1765.
   PubMed Web of Science ®Google Scholar
• Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015;373(3):288–290.
   PubMed Web of Science ®Google Scholar
• McNally B, Ye F, Willette M, et al. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J Virol. 2013;87(23):12916–12924.
   PubMed Web of Science ®Google Scholar
• Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today Barc Spain 1998. 2005;41:107–127.
   Google Scholar
• Yamada T, Moriwaki T, Matsuda K, et al. Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer. Onkologie. 2013;36(4):209–212.
   PubMedGoogle Scholar
• Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20(6):1063–1071.
   PubMed Web of Science ®Google Scholar
• Sanctis AD, Taillade L, Vignot S, et al. Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer. 2011;117(14):3069–3080.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Dafni U, Papadimitriou C, et al. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer. 2014;14:515.
   Google Scholar
• Linden HM, Haskell CM, Green SJ, et al. Sequenced Compared With Simultaneous Anthracycline and Cyclophosphamide in High-Risk Stage I and II Breast Cancer: final Analysis From INT-0137 (S9313). J Clin Oncol. 2007;25(6):656–661.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the Prevention of Breast Cancer: late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. JNCI J Natl Cancer Inst. 2007;99(9):727–737.
   Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: results From the Randomized Phase III TAnDEM Study. J Clin Oncol. 2009;27(33):5529–5537.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Nechushtan H, Ron I-G, et al. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat. 2016;160(2):305–312.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• Baselga J, Morales SM, Awada A, et al. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017;163(3):535–544.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Layman R, Yardley DA, et al. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. Oncologist. 2017;22(3):245–254.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. J Clin Oncol. 2005;23(4):792–799.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. on behalf of the monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. JCO.20.02514.
   PubMed Web of Science ®Google Scholar
• Nicholas, Mark Chemotherapy-Related Drug-Induced Lung Injury [Internet]. Pulmonol. Advis. 2019 [ cited 2020 Aug 17]. cited: https://www.pulmonologyadvisor.com/home/decision-support-in-medicine/pulmonary-medicine/chemotherapy-related-drug-induced-lung-injury/
   Google Scholar
• Lee. Drug-Induced Interstitial Lung Disease [Internet]. [ cited 2020 Aug 19]. Available from: http://www.indianjrheumatol.com/article.asp?=0973-3698;year=2019;volume=14;issue=5;spage=19;epage=26;aulast=Lee
   Google Scholar
• Delaunay M, Prévot G, Collot S, et al. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev [Internet]. 2019 [cited 2020 Aug 20];28. Available from: https://err.ersjournals.com/content/28/154/190012
   Web of Science ®Google Scholar
• Gemma A. Drug-Induced Interstitial Lung Diseases Associated with Molecular-Targeted Anticancer Agents. J Nippon Med Sch. 2009;76(1):4–8.
   PubMedGoogle Scholar
• Ellard SL, Clemons M, Gelmon KA, et al. Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27(27):4536–4541.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther. 2013;30(10):870–884.
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Burris HA, Ito Y, et al. Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421–32.e8.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Park BH, The BOLERO-2. trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol Lond Engl. 2012;8(6):651–657.
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377.
   PubMed Web of Science ®Google Scholar
• Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19(1):18.
   PubMedGoogle Scholar
• Johnston S, Basik M, Hegg R, et al. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast Cancer Res Treat. 2016;160(1):91–99.
   PubMed Web of Science ®Google Scholar
• Schott AF, Barlow WE, Van Poznak CH, et al. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat. 2016;159(1):87–95.
   PubMed Web of Science ®Google Scholar
• Clemens MR, Gladkov OA, Gartner E, et al. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1):171–179.
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, et al. First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: results of a Prospective, Randomized Phase III Study. J Clin Oncol. 2012;30(9):921–929.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Pivot X, Cortés J, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013;22(5):650–656.
   PubMed Web of Science ®Google Scholar
• Boccardo F, Amadori D, Guglielmini P, et al. Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer. Oncology. 2010;78(3–4):274–281.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Dafni U, Gogas H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853–860.
   PubMed Web of Science ®Google Scholar
• Harvey V, Mouridsen H, Semiglazov V, et al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. J Clin Oncol. 2006;24(31):4963–4970.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Coniglio D, Broadwater G, et al. Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metastatic Breast Cancer in Complete Remission Compared with Intensive Standard-Dose Chemotherapy Alone. Biol Blood Marrow Transplant. 2006;12:195–203.
   PubMed Web of Science ®Google Scholar
• Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005;16(6):899–908.
   PubMed Web of Science ®Google Scholar
• Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366(9501):1935–1944.
   PubMed Web of Science ®Google Scholar
• Schmid P, Schippinger W, Nitsch T, et al. Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: results of a Randomized Trial. J Clin Oncol. 2005;23(3):432–440.
   PubMed Web of Science ®Google Scholar
• Paridaens R, Van Aelst F, Georgoulias V, et al. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol. 2003;14(3):433–440.
   PubMed Web of Science ®Google Scholar
• Wardley AM, Hiller L, Howard HC, et al. with on behalf of the tAnGo trial collaborators. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. Br J Cancer. 2008;99:597–603.
   PubMed Web of Science ®Google Scholar
• Ochoa R, Bejarano PA, Glück S, et al. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Reports. 2012;6:413.
   Google Scholar
• Breast cancer drug Verzenio could have serious side effects on lungs, Japan’s health ministry warns | The Japan Times [Internet]. [ cited 2020 Sep 29]. Available from: https://www.japantimes.co.jp/news/2019/05/17/national/science-health/breast-cancer-drug-verzenio-serious-side-effects-lungs-japans-health-ministry-warns/
   Google Scholar
• Palbociclib Related Pnemotoxicity: A Rare Side Effect | C43. DRUG INDUCED LUNG DISEASE: CASE REPORTS. Am Thorac Soc Int Conf Meet Abstr Am Thorac Soc Int Conf Meet Abstr [Internet]. [ cited 2020 Sep 29]; Available from:
   Google Scholar
• Gong J, Cho M, Yu KW, et al. A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 2018;168(2):381–387.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547.
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5(1):5.
   PubMedGoogle Scholar
• Research C for DE and. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. FDA [Internet]. 2019 [ cited 2020 Sep 29]; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer
   Google Scholar
• Müller NL, White DA, Jiang H, et al. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91(S2):S24–30.
   PubMedGoogle Scholar
• Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39.
   PubMed Web of Science ®Google Scholar
• Torrisi JM, Schwartz LH, Gollub MJ, et al. CT Findings of Chemotherapy-induced Toxicity: what Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity. Radiology. 2011;258(1):41–56.
   PubMed Web of Science ®Google Scholar
• Distefano G, Fanzone L, Palermo M, et al. HRCT Patterns of Drug-Induced Interstitial Lung Diseases: a Review. Diagnostics. Internet]. 2020 [cited 2020 Aug 27];10. Available from;. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236658/
   Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–42.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: american Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Chap L, Shpiner R, Levine M, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant. 1997;20(12):1063–1067.
   PubMed Web of Science ®Google Scholar
• Raissy H Pharmacotherapy: a Pathophysiologic Approach, [Internet]. 10th ed. United States of America: McGraw Hill; 2017 [ cited 2021 Oct 18]. cited: https://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=146078953
   Google Scholar